Neuroprotection in cerebral ischemia: Experience with human recombinant erythropoietin;Neuroprotección en la isquemia cerebral. Experiencias con la eritropoyetina humana recombinante

Revista Ecuatoriana de Neurologia

Volumn 16, Issue 2, 2007, Pages 133-143

  Testé, Iliana Sosa ^a,c   García Salman, Jorge Daniel ^b  

^a Universidad Agraria de la Habana   (Cuba)

^b INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA   (Cuba)

^c CENPALAB   (Cuba)

Author keywords

Cerebral ischaemia; Erythropoietin; Intranasal route; Neuroprotection

Indexed keywords

IMMUNOGLOBULIN E;

ADULT; ANGIOSTRONGYLUS CANTONENSIS; CHILD; CONTROLLED STUDY; CUBA; HUMAN; INCIDENCE; MENINGOENCEPHALITIS; NEUROIMMUNOLOGY; REVIEW; WESTERN HEMISPHERE;

EID: 36348981585     PISSN: 10198113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Annual Health Statistcs report, 1999, 21.
2. Hill MD, Hachinski V. Stroke treatment: Time is brain. Lancet 1998, 352 (Suppl): 10-14.
3. Miranda Q. J. A. Enfermedades cerebrovasculares. Editorial Oriente. Instituto Cubano del Libro, 2004.
4. Lainez J.M., Santonja J.M. Historia natural de la enfermedad vascular cerebral. En: Castillo J, Alvarez, Sabin J, Marti Vilalta JL, Martinez E, Matias Guiu J. Manual de enfermedades vasculares cerebrales. JR Prous, 55, 1999.
5. Rodríguez M. L., Galvizu S.R., Alvarez G.E. Neuromodulación farmacológica en la enfermedad cerebrovascular. Temas actualizados. Rev. Cubana Med 2002, 41(2).
6. Fisher M. Finklestein S.P., Furlan J.A., Goldstein B.L., Gorelinck RB., Kaste M., Kennedy R.L., Traysman R.J. Recommendations for standarts regarding preclinical neuroprotective and restorative drug develoment. Stroke 1999, 30, 2752.
7. García Salman J.D. Protección neuronal endógena: un enfoque alternativo. Rev Neurol 2004, 38(2), 150.
8. Dirnagl U, Simon RP, Hallenbeck JM. Isquemic tolerance and endogenous neuroprotection. Trends in Neurocience 2003, 26 (5): 248-254.
9. García Salman J.D. Protección neuronal endógena: un enfoque alternativo. Rev Neurol 2004; 38(2): 150.
10. Dirnagl U, Simon RP, Hallenbeck JM. Isquemic tolerance and endogenous neuroprotection. Trends in Neurocience 2003; 26 (5): 248-254.
11. Villa Pia, Bigini P., Mennini Tiziana, Agnello D., Laragione Teresa, Cagnotto A., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971.
12. Weiss MJ. New Insights into erythropoietin alfa: Mechanisms of Action, Target Tissues, and clinical application. Oncologist 2003; 18 (Suppl 3).
13. Sakanaka M, Wen TC, Matsuda S, Masuda S., Morishita E, Nagao M, and Sasaki E. In vivo evidence that eritropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998; 95:4635-4640.
14. Marti H.H. Erythopoietin and hypoxic brain. Review article. Journal of Experimental Biology 2004; 207: 3233.
15. Van der Meer P, Voors A., Lipsic E, van Gilst W, van Veldhuisen D. Erythropoietin in cardiovascular diseases. European Heart Journal 2004; 25(4): 285-291.
16. Castillo J, Martí-Vilalta JL, Martínez-Vila E, Matías-Guiu J. Manual de enfermedades vasculares cerebrales. Barcelona, España, 1999.
17. Guevara García Mariela, Rodríguez Raisa, Álvarez León Alina, Riaño Montalvo Annia, Rodríguez P.C. Mecanismos celulares y moleculares de la enfermedad cerebrovascular isquémica, Rev Cubana Med 2004; 43(4).
18. Fisher M. El objetivo del tratamiento en la enfermedad cerebrovascular aguda y los enfoques terapéuticos neuroprotectores. Rev Neurol 1999; 29:536-544.
19. Castillo J, Rodríguez I. (). Biochemical Changes and Inflammatory Response as Markers for Brain Ischaemia: Molecular Markers of Diagnostic Utility and Prognosis in Human Clinical Practice. Cerebrovascular Diseases 2004; 17:7-18.
20. Romano J G.. Tratamiento Agudo del Infarto Cerebral. Revista Ecuatoriana de Neurología 2005; (14): 1-3
21. Hossmann K. A. Pathophysiology and Therapy of Experimental Stroke. Cellular and Molecular Neurobiology 2006; (26): 7/8, October/November.
22. Kwakkel G, Kollen B, Lindeman E. Understanding the pattern of functional recovery after stroke: Facts and theories. Restorative Neurology and Neuroscience 2004; 22:281-299.
23. Dombovy ML, Bach-y-Rita. P. Clinical observations on recovery from stroke. Adv Neurol 1988; 47: 265-276.
24. Danica B. Stanimirovic, Dejan V. Micic, Marina Markovic, Maria Spatz, Bogomir B. Mrsulja. Therapeutic window for multiple drug treament of experimental cerebral ischemia in gerbils. Neurochemical 1994; Vol 19(2): 189-194.
25. NINDS rt-PA stroke study group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
26. Pérez Asensio FJ. Isquemia cerebral focal transitoria en rata: caracterización y utilidad del modelo de la sutura intraluminal en el estudio de estrategias neuroprotectoras. Tesis para optar al grado de doctor en ciencias biológicas. Universidad de Valencia, 2005.
27. Dorman PJ, Counsell CE, Sandercock AG. Recently developed neuroprotective therapies for acute stroke. A qualitative systematic review of clinical trials. CNS Drugs 1996; 5:457-74.
28. Takano K, Tatlisumak T, Formato J. A glycine site antagonist attenuates infarct size in experimental focal ischemia: postmortem and diffusion mapping studies. Stroke 1997; 28: 1255-63.
29. Sirén AL y Ehrenreich H. EPO - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001; 251: 179-184.
30. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004; 10:93-98.
31. Karonen JO, Vanninen RL, Liu Y, Ostergaard L, Kuikka JT, Nuutinen J, Vanninen EJ, Partanen PL, Vainio PA, Korhonen K, Perkiö J, Roivainen R, Sivenius J, HJ. A Combined diffusion and perfusion MRI with correlation to single-photon. Stroke 1999; 30:1583-1590.
32. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 1981; 12: 723-725.
33. Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000;20:1276-1293.
34. Muir K.W. and Grosset D.G. Neuroprotection for acute stroke. Making clinical trials work. Stroke 1999; 30,180.
35. Weih, M., Kallenberg, K., Bergk, A., Dirnagl, U., Harms, L., Wernecke, K.D., and Einhaupl, K.M. Attenuated stroke severity after prodromal TIA: A role for ischemic tolerance in the brain? Stroke 1999; 30:1851-1854.
36. Prass, K., Scharff, A., Ruscher, K., Lowl, D., Muselmann, C., Victorov, I., Kapinya, K., Dirnagl, U., and Meisel, A. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003; 34:1981-1986.
37. García-Galloway E, Arango C, Pons S, Torres-Alemán I. Glutamate excitotoxicity attenuates insulin-like growth factor-I prosurvival signaling. Mol Cell Neurosci 2003; 24:1027-37.
38. Cardona-Gómez GP, Arango-Dávila C, Gallego-Gómez JC, Pimienta H, García-Segura LM. Estrogen inhibits glycogen synthase kinase-3b and modulates the interaction of the microtubule-associated protein Tau with glutamate receptor subunits in post-ischemic hippocampus: implications for hormonal neuroprotective mechanisms. Mol Brain Res 2004; 25:178-187.
39. Doppenberg, E.M; Choi, S.C; Bullock, R. Clinical trials in traumatic brain injury: what can we learn from previous studies? Neuroprotective agents - Third international conference. Ann NY Acad Sci 1997; 825:305-22.
40. Diener H-C. For the European and Australian Lubeluzole Ischemic Satroke Study Group Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. Cerebrovascular Diseases 1998; 8:172.
41. Grotta J. For the US and Canadian Lubeluzole Ischemic Stroke Study Group Lubeluzale treatment of acute ischemic stroke. Stroke 1997; 28: 2338.
42. Davis S.M., Alber G.W, Diener H.C., Lees K.R. and Norris J. Termination of acute stroke studies involving selfotel treatment: ASSIST Steering Committee. Lancet 1997; 32:349.
43. Fisher M. The ischemic penumbra - identification, evolution and treatment concepts. Cerebrovasc Dis 2004; 17(1):1-6.
44. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Ugeskr Laeger 2004; 101: 9855.
45. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-659.
46. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997; 378:609-616.
47. Gassmann M, Heinicke K, Soliz J, Ogunshola OO, Marti HH, Hofer T, Grimm C, Heinicke I, Egli B. Non-erythroid functions of erythropoietin. Adv Exp Med Biol 2003; 543:323.
48. Kalialis LV, Olsen NV. Erythropoietin - a new therapy in cerebral ischemia?. Ugeskr Laeger 2003; 165: 2477.
49. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection: what is the evidence?. Clin Breast Cancer 2002; 3: 109-15.
50. Marti H, Bernaudin M, Petit E, Bauer C. Neuroprotection and Angiogenesis: Dual role of erythropoietin in brain ischemia. News of Physiology Science 2000; 15: 225-229.
51. Lipšic E, Schoemaker R., van der Meer P, Voors A., van Veldhuisen D., van Gilst W. Protective effects of erythropoietin in cardiac ischemia: from bench to bed-side. 2006; Chapter 8.
52. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-651.
53. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8:666-676.
54. Juul SE, Anderson DK, Li Y, et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43:40-49.
55. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98:4044-4049.
56. Leist M, Ghezzi P, Grasso G. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
57. Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, Squadrito F, Caputi AP, Calapai G. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur. J. Pharmacol 2002; 437: 147-150.
58. Belayev L, Khoutorova L, Zhao W, et al. Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 2005;36:1071-1076.
59. Siren AL, Knerlich F, Poser W. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001; 101: 271-276.
60. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998; 253: 26-32.
61. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 349-356.
62. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000; 59: 419-425.
63. Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of eripthopoietin alfa. Nephrol Dial Transplant 2002; 17 (Suppl 1), 8.
64. Olsen NV. Central nervous system frontiers for the use of erythropoietin. Clin Infect Dis, 37 (Suppl 4), S323, 2003.
65. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002; 91, 36-42.
66. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-2979.
67. Agnello D, Bigini P, Villa P, Mennini T, Ceremi A, Brines M, Ghezzi P. Erythropoietin exerts anti-inflammatory effect on the center nerves system in the model of experimental autoinmune encephalomyelitis. Brain Res 2002;952: 128-134.
68. Arango-Davila C, Escobar-Betancourt M, Cardona-Gómez GP, Pimienta-Jiménez H. Fisiopatología de la isquemia cerebral focal: aspectos básicos y proyección a la clínica. Rev Neurol 2004; 39 (2): 156-165.
69. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003; 138: 1107-1118.
70. Nagai A, Nakagawa E, Choi HB. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60:386-392.
71. Anagnostou A, Lee ES, Kessimian N. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990; 87:5978-5982.
72. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22:10291-10301.
73. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
74. Alafaci C, Salpietro F, Grasso G. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406: 219-225.
75. Sinn D, Chu K, Lee S, et al. Erythropoietin has neuroprotective effects with functional recovery in experimental intracerebral hemorrhage. 57th Annual Meeting of the American Academy of Neurology. 2005; S48.008:http://www. abstracts2view.com/aan/
76. Lu D, Mahmood A, Qu C, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005; 22:1011-1017.
77. Yatsiv I, Grigoriadis N, Simeonidou C. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. Faseb J 2005.
78. Lu D, Mahmood A, Qu C. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma. 2005; 22:1011-1017.
79. Celik M, Gokmen N, Erbayraktar S. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002; 99:2258-2263.
80. Gorio A, Gokmen N, Erbayraktar S. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002; 99:9450-9455.
81. Li W, Maeda Y, Yuan RR, et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004;56:767-777.
82. Zhang J, Li Y, Cui Y. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005;1034:34-39.
83. Sattler MB, Merkler D, Maier K, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Dier 2004; 11 (Suppl 2): S181-S192.
84. Diem R, Sattler MB, Merkler D. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005;128:375-385.
85. Bianchi R, Buyukakilli B, Brines M. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004; 101:823-828.
86. Becerra SP, Amaral J. Erythropoietin - an endogenous retinal survival factor. N Engl J Med 2002;347:1968-1970.
87. Yatsiv I, Grigoriadis N, Simeonidou C. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. Faseb J. 2005.
88. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9:42-54.
89. Sola A, Rogido M, Lee BH, et al. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 2005; 57: 481-487.
90. Kumral A, Gonenc S, Acikgoz O. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 2005; 87:15-18.
91. Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005;58:106-111.
92. Weiss Mitchell J. New Insights into erythropoietin alfa: Mechanisms of Action, Target Tissues, and clinical aplication. Oncologist 2003; 18, Suppl 3.
93. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489-498.
94. Shingo T., Soracan S.T., Shimazaki T., Weis S. Erythropoietin regulates the in vitro and production of neuronal progenitors be mammalian forebrain neural stem cells. J Neurosci 2001; 21:9733-9743.
95. Wang L. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732.
96. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LO, Cerami-Hand C, Wuerth JP, Cerami A, Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100:6741-6746.
97. Sakane, T., Akizuki, M., Yoshida M., Yamashita, S., Nadai, T., Hashida M., and Sezaki H. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 2000;43: 449-451.
98. Frey HW, Liu J, Chen X, Thoner RG, Fawcett JR, Ala TA, Rahman YE. Delivery of 125 I-NGF to the brain via the olfatory Route. Drug Delivery 1997; 4: 87-92.
99. Thorne RG, Emory CR, Ala TA, Frey WH. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995; Sep 18;692(1-2):278-82.
100. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005; Oct 14,387(1):5-10.
101. Subirós Nelvis, García Rodriguez JC, Gonzalez B, Sosa I, García Salman JD. Evaluación histológica del efecto de la Eritropoyetina vía intranasal, sobre la muerte neuronal retardada en gerbos sometidos a isquemia cerebral transitoria. Estudio preliminar. 7° Congreso Virtual Hispanoamericano de Anatomía Patológica 2005 ; http://www.conganat.org/445.pdf.
102. Sosa I, García Rodríguez JC, García Salman JD, Subiras N, González C, Rodríguez Ya, Delgado R, Santana J. Eritropoyetina humana recombinante (rHu-EPO CIM) por vía nasal como neuroprotector en el Ictus. Libra resumen Congreso Caribeño de ICTUS 2005; Santiago de Cuba.
103. Sosa I, García Rodríguez JC, García Salman JD, Santana J, Subirós N, González C, Rodríguez J, Cruz J. Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacologyonline 2006;.1: 100-112.
104. Hilger PA. Applied anatomy and physiology of the nose. In Boies Fundamentals of Otolaryngology, 6tht ed., ed. G.L Adams, L.R. Boies, and P.A Hilger, Philadelphia: W. B. Saunders 1989;177-195.
105. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 7: 187-198.
106. Banks AW. Are the extracelluar pathways a conduit for the delivery of therapeutics to the brain? Current Pharmaceutical Design 2004; 10:1365-70.
107. Sosa I; Cruz J, Santana J.; Mengana Y, García-Salman JD; Muñoz A; García T; García Rodríguez JC. Paso de la molécula de eritropoyetina humana recombinante con bajo contenido de ácido siálico al sistema nervioso central por la vía intranasal en los modelos del Meriones unguiculatus y el primate no humano Macaca fascicularis. Rev Salud Animal In press 2007.
108. Subirós N. Eritropoyetina humana recombinante con bajo contenido de ácidos siálicos. Efecto neuroprotector de su administración nasal sobre la isquemia cerebral. Tesis de Maestría en Neurociencias, Centro de Neurociencias de Cuba. Febrero; 2007.